Human epidermal growth factor receptor-2 antibodies enhance thespecificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes

Biomaterials

Volumn 57, Issue , 2015, Pages 1-11

  Li, Qingpo ^a   Tang, Qin ^b   Zhang, Peizun ^a   Wang, Zuhua ^a   Zhao, Tiantian ^b   Zhou, Jialin ^a   Li, Hongrui ^b   Ding, Qian ^b   Li, Wei ^a   Hu, Fuqiang ^a   Du, Yongzhong ^a   Yuan, Hong ^a   Chen, Shuqing ^a   Gao, Jianqing ^a   Zhan, Jinbiao ^b   You, Jian ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antibody mediated targeted delivery; HER2 antibody; Hollow gold nanospheres; Light sensitive liposomes; Photothermal chemotherapy

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; INFRARED DEVICES; IRRADIATION; LIGHT SENSITIVE MATERIALS; LIPOSOMES; MAMMALS; NANOSPHERES; PHOTOSENSITIVITY; TOXICITY; TUMORS;

ANTI-TUMOR ACTIVITIES; ANTICANCER ACTIVITIES; DRUG DELIVERY SYSTEM; GOLD NANOSPHERES; HUMAN EPIDERMAL GROWTH FACTOR; NIR LASER IRRADIATION; PHOTO-THERMAL; TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOLLOW GOLD NANOSPHERE; LIPOSOME; NANOSPHERE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION; ERBB2 PROTEIN, HUMAN; MACROGOL DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COCULTURE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; HUMAN CELL; IN VIVO STUDY; LASER; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; HYPERTHERMIC THERAPY; LIGHT; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOCONJUGATES; LIGHT; MICE; MICE, NUDE; OVARIAN NEOPLASMS; OVARY; PHOTOTHERAPY; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2;

EID: 84928956471     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.009     Document Type: Article

References (20)

1. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
2. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
3. Zolot R.S., Basu S., Million R.P. Antibody-drug conjugates. Nat Rev Drug Discov 2013, 12:259-260.
4. Fay F., Scott C.J. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 2011, 3:381-394.
5. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007, 4:297-305.
6. Lian T., Ho R.J. Trends and developments in liposome drug delivery systems. JPharm Sci 2001, 90:667-680.
7. Nellis D.F., Giardina S.L., Janini G.M., Shenoy S.R., Marks J.D., Tsai R., et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005, 21:221-232.
8. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65:36-48.
9. You J., Zhang P.Z., Hu F.Q., Du Y.Z., Yuan H., Zhu J., et al. Near-infrared light-sensitive liposomes for the enhanced photothermal tumor treatment by the combination with chemotherapy. Pharm Res 2014, 31:554-565.
10. You J., Zhou J., Zhou M., Liu Y., Robertson J.D., Liang D., et al. Pharmacokinetics, clearance, and biosafety of polyethylene glycol-coated hollow gold nanospheres. Part Fibre Toxicol 2014, 11:26.
11. Shen H., You J., Zhang G., Ziemys A., Li Q., Bai L., et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater 2012, 1:84-89.
12. You J., Zhang G., Li C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. Acs Nano 2010, 4:1033-1041.
13. You J., Zhang R., Xiong C., Zhong M., Melancon M., Gupta S., et al. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res 2012, 72:4777-4786.
14. You J., Wang Z., Du Y., Yuan H., Zhang P., Zhou J., et al. Specific tumor delivery of paclitaxel using glycolipid-like polymer micelles containing gold nanospheres. Biomaterials 2013, 34:4510-4519.
15. Olayioye M.A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res BCR 2001, 3:385-389.
16. Burstein H.J. The distinctive nature of HER2-positive breast cancers. NEngl J Med 2005, 353:1652-1654.
17. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529.
18. Hellstrom I., Goodman G., Pullman J., Yang Y., Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001, 61:2420-2423.
19. Tai W., Mahato R., Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. JControl Release 2010, 146:264-275.
20. Weiss R.B. The anthracyclines - will we ever find a better doxorubicin. Semin Oncol 1992, 19:670-686.